Difference in Efficacy and Safety of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Containing 4-1BB and CD28 Co-Stimulatory Domains for B-Cell Acute Lymphoblastic Leukemia

SIMPLE SUMMARY: To date, quantitative and comprehensive information summarizing the differences in the efficacy and safety of anti-CD19 chimeric antigen receptor (CAR) T-cells with CD28 co-stimulatory domains or 4-1BB co-stimulatory domains for the treatment of B-cell acute lymphoblastic leukemia (B...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Lijuan, Chen, Junchao, Cai, Ruifen, Wang, Xinrui, Liu, Yixiao, Zheng, Qingshan, Li, Lujin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216493/
https://www.ncbi.nlm.nih.gov/pubmed/37345104
http://dx.doi.org/10.3390/cancers15102767

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216493/
https://www.ncbi.nlm.nih.gov/pubmed/37345104
http://dx.doi.org/10.3390/cancers15102767

Ejemplares similares